TAVALISSE

This brand name is authorized in Canada, Israel, Japan, United States

Active ingredients

The drug TAVALISSE contains one active pharmaceutical ingredient (API):

1 Fostamatinib UNII SQ8A3S5101 - FOSTAMATINIB

Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK), through its major metabolite R406. R406 reduces antibody-mediated destruction of platelets. Fostamatinib is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients. Read about Fostamatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TAVALISSE Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BX09		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02508052, 02508060
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8792, 8793
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999058F1026, 3999058F2022
Country: US	FDA, National Drug Code	Identifier(s): 71332-001, 71332-002